Dronedarone for atrial fibrillation: a new therapeutic agent
| Autor: | Rohit R Arora, Rohit Bhuriya, Pawan D. Patel, Param Singh, Bhaskar Arora, Dipal Patel |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Side effect Endocrinology Diabetes and Metabolism Amiodarone macromolecular substances Review Heart Rate dronedarone Internal medicine Heart rate Atrial Fibrillation medicine Animals Humans Pharmacology (medical) Adverse effect Randomized Controlled Trials as Topic Evidence-Based Medicine business.industry Public Health Environmental and Occupational Health Atrial fibrillation Hematology General Medicine medicine.disease Dronedarone Treatment Outcome Cardiac rhythm disturbances Anesthesia Cardiology cardiovascular system Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | Vascular Health and Risk Management |
| ISSN: | 1178-2048 |
| Popis: | Atrial fibrillation is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Amiodarone is currently one of the most widely used and most effective antiarrhythmic agents for atrial fibrillation. But during chronic usage amiodarone can cause some serious extra cardiac adverse effects, including effects on the thyroid. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile. Dronedarone is a multichannel blocker and, like amiodarone, possesses both a rhythm and a rate control property in atrial fibrillation. The US Food and Drug Administration approved dronedarone for atrial fibrillation on July 2, 2009. In this review, we discuss the role of dronedarone in atrial fibrillation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|